Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by StockNews.com

Analysts at StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note issued on Monday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

Shares of Ayala Pharmaceuticals stock opened at $0.03 on Monday. The firm’s 50 day moving average price is $0.03 and its 200-day moving average price is $0.04. Ayala Pharmaceuticals has a 52-week low of $0.00 and a 52-week high of $0.78. The company has a market cap of $1.28 million, a P/E ratio of 0.00 and a beta of 1.68.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.